Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Danilov AV, Spurgeon SE, Siddiqi T, Quinson AM, Maier D, Smith D, Brown JR. Danilov AV, et al. Among authors: siddiqi t. Invest New Drugs. 2021 Aug;39(4):1099-1105. doi: 10.1007/s10637-020-01056-4. Epub 2021 Mar 8. Invest New Drugs. 2021. PMID: 33683501 Free PMC article. Clinical Trial.
The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model.
Gordon MJ, Kaempf A, Sitlinger A, Shouse G, Mei M, Brander DM, Salous T, Hill BT, Alqahtani H, Choi M, Churnetski MC, Cohen JB, Stephens DM, Siddiqi T, Rivera X, Persky D, Wisniewski P, Patel K, Shadman M, Park B, Danilov AV. Gordon MJ, et al. Among authors: siddiqi t. Clin Cancer Res. 2021 Sep 1;27(17):4814-4824. doi: 10.1158/1078-0432.CCR-20-3993. Epub 2021 Jun 24. Clin Cancer Res. 2021. PMID: 34168050 Free PMC article.
Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.
Kambhampati S, Saumoy M, Schneider Y, Pak S, Budde LE, Mei MG, Siddiqi T, Popplewell LL, Wen YP, Zain J, Forman SJ, Kwak LW, Rosen ST, Danilov AV, Herrera AF, Thiruvengadam NR. Kambhampati S, et al. Among authors: siddiqi t. Blood. 2022 Dec 22;140(25):2697-2708. doi: 10.1182/blood.2022016624. Blood. 2022. PMID: 35700381 Free PMC article.
Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma.
Kambhampati S, Saumoy M, Schneider Y, Serrao S, Solaimani P, Budde LE, Mei MG, Popplewell LL, Siddiqi T, Zain J, Forman SJ, Kwak LW, Rosen ST, Danilov AV, Herrera AF, Thiruvengadam NR. Kambhampati S, et al. Among authors: siddiqi t. Blood. 2022 Nov 10;140(19):2024-2036. doi: 10.1182/blood.2022016747. Blood. 2022. PMID: 35914220 Free PMC article.
Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia.
Ujjani C, Gooley TA, Spurgeon SE, Stephens DM, Lai C, Broome CM, O'Brien S, Zhu H, Laing KJ, Winter AM, Pongas G, Greninger AL, Koelle DM, Siddiqi T, Davids MS, Rogers KA, Danilov AV, Sperling A, Tu B, Sorensen T, Launchbury K, Burrow CJ, Quezada G, Hill JA, Shadman M, Thompson PA. Ujjani C, et al. Among authors: siddiqi t. Blood Adv. 2023 Sep 12;7(17):4728-4737. doi: 10.1182/bloodadvances.2022009164. Blood Adv. 2023. PMID: 36516082 Free PMC article.
Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy.
Lee K, Iukuridze A, He T, Bosworth A, Lindenfeld L, Teh JB, Echevarria M, Albanese S, Atencio L, Bhandari R, Wong FL, Artz AS, Siddiqi T, Nikolaenko L, Zain J, Mei M, Shouse G, Popplewell LL, Herrera AF, Budde LE, Forman SJ, Armenian SH. Lee K, et al. Among authors: siddiqi t. J Natl Compr Canc Netw. 2023 Apr;21(4):373-382.e1. doi: 10.6004/jnccn.2022.7100. J Natl Compr Canc Netw. 2023. PMID: 37015335
Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia.
Wang X, Chen C, Vuong D, Rodriguez-Rodriguez S, Lam V, Roleder C, Wang JH, Kambhampati S, Berger A, Pennock N, Torka P, Hernandez-Ilizaliturri F, Siddiqi T, Wang L, Xia Z, Danilov AV. Wang X, et al. Among authors: siddiqi t. Leukemia. 2023 Jun;37(6):1324-1335. doi: 10.1038/s41375-023-01889-x. Epub 2023 Apr 8. Leukemia. 2023. PMID: 37031300 Free PMC article.
METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL.
Wu Y, Jin M, Fernandez M, Hart KL, Liao A, Ge X, Fernandes SM, McDonald T, Chen Z, Röth D, Ghoda LY, Marcucci G, Kalkum M, Pillai RK, Danilov AV, Li JJ, Chen J, Brown JR, Rosen ST, Siddiqi T, Wang L. Wu Y, et al. Among authors: siddiqi t. Blood Cancer Discov. 2023 May 1;4(3):228-245. doi: 10.1158/2643-3230.BCD-22-0156. Blood Cancer Discov. 2023. PMID: 37067905 Free PMC article.
334 results